Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Mattía Galli(Maria Cecilia Hospital), Sebastiano Sciarretta(Istituto Neurologico Mediterraneo), Roxana Mehran(Mount Sinai Hospital), Gianmarco Sarto(Sapienza University of Rome), Domenico D’Amario(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Claudio Laudani(University of Florida), Filippo Crea(Università Cattolica del Sacro Cuore), Massimo Federici(University of Rome Tor Vergata), Erica Rocco(Sapienza University of Rome), Marco Bernardi(Policlinico Umberto I), Ernesto Greco(European University of Rome), Giacomo Frati(Istituto Neurologico Mediterraneo), Stefano Benenati(Ospedale Policlinico San Martino), Dominick J Angiolillo(University of Florida), Luis Ortega‐Paz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Beatrice Simeone(Sapienza University of Rome), Luigi Spadafora(Policlinico Umberto I)
Cited by 48
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k